Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 InnovivaProtagonist TherapeuticsORIC PharmaceuticalsAkero TherapeuticsAclaris Therapeutics
SymbolNASDAQ:INVANASDAQ:PTGXNASDAQ:ORICNASDAQ:AKRONASDAQ:ACRS
Price Information
Current Price$11.90$26.55$21.33$27.34$26.68
52 Week RangeSellBuyBuyBuyN/A
MarketRank™
Overall Score1.41.51.71.70.8
Analysis Score0.53.53.44.50.0
Community Score2.12.23.02.52.6
Dividend Score0.00.00.00.00.0
Ownership Score3.31.71.71.70.8
Earnings & Valuation Score1.30.00.60.00.6
Analyst Ratings
Consensus RecommendationSellBuyBuyBuyN/A
Consensus Price Target$10.00$38.00$43.71$57.29N/A
% Upside from Price Target-15.97% downside43.13% upside104.94% upside109.53% upsideN/A
Trade Information
Market Cap$1.21 billion$1.16 billion$782.70 million$950.61 million$1.38 billion
Beta0.641.56N/A0.581.2
Average Volume546,174368,796281,962291,2162,685,047
Sales & Book Value
Annual Revenue$261.02 million$230,000.00N/AN/A$4.23 million
Price / Sales4.625,056.97N/AN/A326.74
Cashflow$1.69 per shareN/AN/AN/AN/A
Price / Cash7.03N/AN/AN/AN/A
Book Value$3.38 per share$2.94 per shareN/A$4.51 per share$1.69 per share
Price / Book3.529.03N/AN/A15.79
Profitability
Net Income$157.29 million$-77,190,000.00N/A$-43,760,000.00$-161,350,000.00
EPS$1.43($2.98)N/A($2.90)($2.25)
Trailing P/E Ratio6.07N/A0.00N/AN/A
Forward P/E Ratio6.92N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins67.16%-252.03%N/AN/A-941.07%
Return on Equity (ROE)53.99%-54.00%N/A-40.84%-104.00%
Return on Assets (ROA)28.92%-35.38%N/A-38.33%-64.47%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.72%N/AN/AN/A0.26%
Current Ratio146.75%5.29%27.29%24.81%4.54%
Quick Ratio146.75%5.29%27.29%24.81%4.54%
Ownership Information
Institutional Ownership Percentage71.48%97.45%73.42%83.49%59.10%
Insider Ownership Percentage0.32%14.20%N/A7.09%8.20%
Miscellaneous
Employees579611657
Shares Outstanding101.39 million43.81 million36.70 million34.77 million51.80 million
Next Earnings Date5/5/2021 (Estimated)5/6/2021 (Estimated)5/19/2021 (Estimated)5/12/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 41.5% in MarchAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 41.5% in March
americanbankingnews.com - April 18 at 1:14 AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) share price rebounds 96.18% from the lows – but can it keep going?Aclaris Therapeutics, Inc. (NASDAQ:ACRS) share price rebounds 96.18% from the lows – but can it keep going?
marketingsentinel.com - April 17 at 6:00 PM
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 5.6%Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 5.6%
americanbankingnews.com - April 13 at 3:22 PM
Zacks: Analysts Anticipate Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Will Post Earnings of -$0.26 Per ShareZacks: Analysts Anticipate Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Will Post Earnings of -$0.26 Per Share
americanbankingnews.com - April 12 at 8:14 PM
Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 1-Year High at $29.27Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 1-Year High at $29.27
americanbankingnews.com - April 5 at 1:28 PM
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Up to $25.20Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Up to $25.20
americanbankingnews.com - April 1 at 12:08 PM
Aclaris Therapeutics Stock Appears To Be Significantly OvervaluedAclaris Therapeutics Stock Appears To Be Significantly Overvalued
finance.yahoo.com - April 1 at 8:23 AM
Aclaris Therapeutics (NASDAQ:ACRS) Shares Up 5.6%Aclaris Therapeutics (NASDAQ:ACRS) Shares Up 5.6%
americanbankingnews.com - March 25 at 11:37 AM
Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Hold at Zacks Investment ResearchAclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Hold at Zacks Investment Research
marketbeat.com - March 23 at 4:46 PM
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for ...Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for ...
apnews.com - March 16 at 9:44 AM
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic DermatitisAclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
finance.yahoo.com - March 15 at 8:29 AM
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a ...Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a ...
apnews.com - February 26 at 9:58 AM
Aclaris: 4Q Earnings Snapshot | Raleigh News & ObserverAclaris: 4Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - February 25 at 1:29 PM
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate UpdateAclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
finance.yahoo.com - February 25 at 8:29 AM
Aclaris Therapeutics to Participate in Upcoming Investor ConferencesAclaris Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 22 at 9:00 AM
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceAclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 10 at 9:06 AM
Gaining Ground After A Tough Couple Of WeeksGaining Ground After A Tough Couple Of Weeks
finance.yahoo.com - January 25 at 7:34 PM
Aclaris aims to raise $96 million through stock offering after shares soarAclaris aims to raise $96 million through stock offering after shares soar
bizjournals.com - January 20 at 9:29 PM
Aclaris Therapeutics stock jumps on positive data for drug developed by St. Louis-based unitAclaris Therapeutics' stock jumps on positive data for drug developed by St. Louis-based unit
bizjournals.com - January 20 at 4:22 PM
How High Is the Blue Sky for Aclaris Stock? Analyst Weighs InHow High Is the Blue Sky for Aclaris Stock? Analyst Weighs In
finance.yahoo.com - January 20 at 4:21 PM
Aclaris Announces Pricing of Public Offering of Common StockAclaris Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 20 at 11:21 AM
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RAAclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
finance.yahoo.com - January 20 at 11:21 AM
Aclaris Explodes 220% On ‘Positive Data’ From Rheumatoid Arthritis TrialAclaris Explodes 220% On ‘Positive Data’ From Rheumatoid Arthritis Trial
finance.yahoo.com - January 20 at 6:20 AM
ACRS Soars On RA Trial Data, BHVN Disappoints In Alzheimers Trial, GRTS Joins COVID-19 Vaccine RaceACRS Soars On RA Trial Data, BHVN Disappoints In Alzheimer's Trial, GRTS Joins COVID-19 Vaccine Race
markets.businessinsider.com - January 20 at 1:20 AM
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of ...Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of ...
apnews.com - January 20 at 1:20 AM
Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?
msn.com - January 19 at 8:20 PM
DateCompanyBrokerageAction
11/11/2020InnovivaMorgan StanleyBoost Price Target
6/25/2018InnovivaStifel NicolausReiterated Rating
4/19/2018InnovivaBerenberg BankInitiated Coverage
3/17/2021Protagonist TherapeuticsHC WainwrightBoost Price Target
3/9/2021Protagonist TherapeuticsSVB LeerinkBoost Price Target
1/6/2021Protagonist TherapeuticsJPMorgan Chase & Co.Initiated Coverage
12/16/2020Protagonist TherapeuticsPiper SandlerInitiated Coverage
12/7/2020Protagonist TherapeuticsBMO Capital MarketsBoost Price Target
7/15/2020Protagonist TherapeuticsJefferies Financial GroupInitiated Coverage
5/11/2020Protagonist TherapeuticsNomuraBoost Price Target
5/11/2020Protagonist TherapeuticsNomura InstinetBoost Price Target
8/11/2019Protagonist TherapeuticsNomura SecuritiesReiterated Rating
6/6/2018Protagonist TherapeuticsBarclaysDowngrade
1/25/2021ORIC PharmaceuticalsCitigroupDowngrade
8/12/2020ORIC PharmaceuticalsRobert W. BairdInitiated Coverage
6/19/2020ORIC PharmaceuticalsOppenheimerReiterated Rating
5/19/2020ORIC PharmaceuticalsGuggenheimInitiated Coverage
3/24/2021Akero TherapeuticsCanaccord GenuityLower Price Target
3/23/2021Akero TherapeuticsChardan CapitalBoost Price Target
10/11/2019Aclaris TherapeuticsWilliam BlairReiterated Rating
9/6/2019Aclaris TherapeuticsJMP SecuritiesDowngrade
8/9/2019Aclaris TherapeuticsCantor FitzgeraldReiterated Rating
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.